Hemab raises $157M to lead next wave in rare blood disorder treatments

Hemab Therapeutics secured $157 million in Series C funding to advance innovative therapies for rare, underserved bleeding disorders like Glanzmann thrombasthenia and Von Willebrand disease.

Why it matters: While hemophilia treatments have rapidly advanced, other serious clotting disorders remain overlooked. Hemab’s work could fill that gap with potentially first-in-class therapies and once-monthly dosing treatments for patients with limited options.

Backstory: Hemab is developing antibody drugs that work differently from traditional clotting factor replacements. Its lead candidate, sutacimig, is headed into a pivotal trial for Glanzmann thrombasthenia after having cut annual bleeds by 50%+ in Phase 2, while HMB-002 has shown early proof of its novel mechanism for Von Willebrand disease. A third candidate for Factor VII deficiency is in Phase 2 testing.

Big picture: The funding comes during a resurgence in biotech investment, with October being the most active month for financings in 2025. Hemab’s round was led by Sofinnova and joined by other investors, including Novo Holdings.

Zoom in: These new treatments will likely be quite popular if approved, as once-monthly injections and dual-targeting designs offer a major boost in convenience. According to its CEO, Hemab aims to become the “ultimate coagulation disorders company,” but this will not be an easy task as Roche and Star Therapeutics are also exploring new Von Willebrand treatments, signaling growing interest in this area.